Search results
Showing 61 to 75 of 77 results for psoriasis
guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details
from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Past technology appraisal appeals and decisions
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
In development Reference number: GID-TA11189 Expected publication date: TBC
Apremilast for treating moderate to severe plaque psoriasis (TA368)
This guidance has been updated and replaced by NICE technology appraisal guidance 419. Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
In development Reference number: GID-TA11709 Expected publication date: TBC
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .